Detalles de la búsqueda
1.
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Br J Haematol
; 201(5): 845-850, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36895158
2.
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Br J Haematol
; 201(2): 267-279, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36541152
3.
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Blood
; 136(9): 1091-1104, 2020 08 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32438407
4.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33428632
5.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Br J Haematol
; 192(5): 853-868, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32656799
6.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Haematologica
; 106(7): 1957-1967, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32499244
7.
Subclonal TP53 copy number is associated with prognosis in multiple myeloma.
Blood
; 132(23): 2465-2469, 2018 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373884
8.
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Ann Hematol
; 99(5): 1049-1061, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32236735
9.
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(1): 57-73, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30559051
10.
Successful treatment of chronic myelomonocytic leukaemia with hydroxycarbamide in a patient presenting with acute hypoxic respiratory failure due to COVID-19 pneumonia.
Br J Haematol
; 190(4): e195-e198, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32593202
11.
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.
Cancer Immunol Immunother
; 64(8): 1021-32, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25982371
12.
Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.
Br J Haematol
; 162(1): 107-11, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23614650
13.
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
J Clin Oncol
; 41(23): 3945-3955, 2023 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37315268
14.
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial.
EClinicalMedicine
; 62: 102099, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37554123
15.
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.
Blood
; 116(15): e56-65, 2010 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-20616218
16.
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
J Clin Oncol
; 40(25): 2889-2900, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35377708
17.
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
Clin Lymphoma Myeloma Leuk
; 21(3): 154-161.e3, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33478922
18.
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.
Leuk Lymphoma
; 62(6): 1396-1404, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33356703
19.
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial.
Leukemia
; 35(7): 2043-2053, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33262523
20.
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Leukemia
; 34(7): 1840-1852, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32024950